|Bid||99.00 x 800|
|Ask||299.02 x 800|
|Day's Range||184.61 - 188.88|
|52 Week Range||158.38 - 218.38|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||18.99|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||227.63|
United Therapeutics saw its stock jump after receiving approval from the FDA to launch a new treatment for pulmonary arterial hypertension. Liquidia is pursuing a similar drug.
United Therapeutics stock had its Relative Strength (RS) Rating upgraded from 71 to 89 Tuesday. On a weekly chart, the relative strength line for the biotech stock is sitting at a new high territory, earning it a Blue Dot in MarketSmith. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2022.